Background: Giant cell tumors (GCT) of the pancreas are a rare form of pancreatic cancer. Although data are limited, clinical outcomes appear to depend largely on histological subtype with osteoclastic tumors carrying a better prognosis. We report on a homogenous series of patients with osteoclastic-type GCTs of the pancreas presenting to a national pancreatico-biliary gastrointestinal oncology center. Methods: Patients underwent endoscopic, radiological and histopathological assessments. Data were collected in relation to consecutive patients presenting with osteoclastic-type tumors of the pancreas and analyzed with survival as a primary end point. Results: Four patients were treated over a 4-year period. Median age was 77 years with equal gender distribution. Median tumor size was 42 mm. Histology was osteoclast-type giant cells in all 4 patients. Two patients underwent surgery with curative intent. Median overall survival was 13.1 months. Conclusion: This is the largest reported series of osteoclast-type histology in GCTs of the pancreas.

1.
Loya AC, Ratnakar KS, Shastry RA: Combined osteoclastic giant cell and pleomorphic giant cell tumor of the pancreas: a rarity. An immunohistochemical analysis and review of the literature. JOP 2004;5:220-224.
2.
Watanabe M, Miura H, Inoue H, Uzuki M, Noda Y, Fujita N, et al: Mixed osteoclastic/pleomorphic-type giant cell tumor of the pancreas with ductal adenocarcinoma: histochemical and immunohistochemical study with review of the literature. Pancreas 1997;15:201-208.
3.
Moore JC, Hilden K, Bentz JS, Pearson RK, Adler DG: Osteoclastic and pleomorphic giant cell tumors of the pancreas diagnosed via EUS-guided FNA: unique clinical, endoscopic, and pathologic findings in a series of 5 patients. Gastrointest Endosc 2009;69:162-166.
4.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
5.
Hidalgo M: Pancreatic cancer. N Engl J Med 2010;362:1605-1617.
6.
Nai GA, Amico E, Gimenez VR, Guilmar M: Osteoclast-like giant cell tumor of the pancreas associated with mucus-secreting adenocarcinoma. Case report and discussion of the histogenesis. Pancreatology 2005;5:279-284.
7.
Osaka H, Yashiro M, Nishino H, Nakata B, Ohira M, Hirakawa K: A case of osteoclast-type giant cell tumor of the pancreas with high-frequency microsatellite instability. Pancreas 2004;29:239-241.
8.
Singhal A, Shrago SS, Li SF, Huang Y, Kohli V: Giant cell tumor of the pancreas: a pathological diagnosis with poor prognosis. Hepatobiliary Pancreat Dis Int 2010;9:433-437.
9.
Moore JC, Bentz JS, Hilden K, Adler DG: Osteoclastic and pleomorphic giant cell tumors of the pancreas: a review of clinical, endoscopic, and pathologic features. World J Gastrointest Endosc 2010;2:15-19.
10.
Kobayashi S, Nakano H, Ooike N, Oohashi M, Koizumi S, Otsubo T: Long-term survivor of a resected undifferentiated pancreatic carcinoma with osteoclast-like giant cells who underwent a second curative resection: a case report and review of the literature. Oncol Lett 2014;8:1499-1504.
11.
Sedivy R, Peters K, Klöppel G: Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005;446:41-45.
12.
Machado MA, Herman P, Montagnini AL, Jukemura J, Leite KR, Machado MC: Benign variant of osteoclast-type giant cell tumor of the pancreas: importance of the lack of epithelial differentiation. Pancreas 2001;22:105-107.
13.
Temesgen WM, Wachtel M, Dissanaike S: Osteoclastic giant cell tumor of the pancreas. Int J Surg Case Rep 2014;5:175-179.
14.
Yoshioka M, Uchinami H, Watanabe G, Takahashi T, Nakagawa Y, Andoh H, et al: Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombus. Intern Med 2012;51:2145-2150.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.